Digital Therapeutics Company Signs Massive Agreement For Its Diabetes Treatment
Better Therapeutics Inks Rebate Agreement for AspyreRx Diabetes Treatment with Major US Pharmacy Benefit Manager.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
In an exciting development in the field of digital therapeutics, Better Therapeutics, Inc. (BTTX), a leading developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, has announced signing a rebate agreement with one of the largest Pharmacy Benefit Managers (PBMs) in the United States for its AspyreRx Diabetes Treatment.
The agreement marks a significant milestone for Better Therapeutics and its commitment to making evidence-based, cost-effective treatments available to a wider patient demographic.
The deal between Better Therapeutics and the unnamed PBM promises to revolutionize access to digital therapeutics for diabetes patients across the nation. It will facilitate greater insurance coverage for AspyreRx, making the treatment more affordable for patients who need it most.
AspyreRx is a prescription digital therapeutic (PDT) designed to improve glycemic control in adults with type 2 diabetes. It does this by delivering cognitive behavioral therapy that helps patients make lasting changes to their diet and lifestyle. The treatment has been clinically proven to reduce A1C levels, a key marker of blood glucose control.
The Impact on the Health Industry
This agreement is expected to have a profound impact on the healthcare industry. It signifies a growing acceptance of digital therapeutics as an effective solution for managing chronic diseases like diabetes. Additionally, it could prompt other PBMs and insurance providers to consider similar arrangements, expanding access to these innovative treatments.
The Future of Digital Therapeutics
Better Therapeutics’ recent agreement is a testament to the growing recognition of digital therapeutics in mainstream healthcare. As more PBMs and insurance providers recognize the value of these treatments, it's likely we'll see an increase in their availability and affordability.
Digital therapeutics like AspyreRx represent a new frontier in healthcare, offering an innovative approach to managing chronic diseases. With continued research and development, these treatments have the potential to transform the lives of millions of patients around the world.
As we look towards the future, the role of digital therapeutics in healthcare will only continue to grow. And with companies like Better Therapeutics leading the way, it's an exciting time to be part of this rapidly evolving field.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources:
